Loading organizations...
§ Private Profile · Waltham, MA, USA
Develops antibody therapies designed to cross the blood-brain barrier for neurodegenerative diseases, focused on Alzheimer's.
Korsana Biosciences, headquartered in Waltham, Massachusetts, is pioneering antibody therapies engineered to effectively cross the blood-brain barrier, addressing neurodegenerative diseases with an initial focus on Alzheimer's disease. The company has successfully raised $175 million in total funding, comprising a $25 million seed round in 2024 and a significant $150 million Series A in September 2025. Jonathan Violin, Ph.D., a seasoned leader and previously founding CEO of Viridian Therapeutics, spearheads Korsana as CEO, having also founded the company in 2024. Its lead candidate, KRSA-028, discovered through a strategic partnership with Paragon Therapeutics, is specifically designed to target amyloid beta plaques by binding to transferrin receptors, aiming to advance treatments while avoiding adverse side effects like brain swelling. Key investors, including Wellington Management, TCGX, J.P. Morgan Life Sciences Private Capital, and Sanofi Ventures, back Korsana's mission, with KRSA-028 anticipated to enter clinical trials in early 2027.
Korsana Biosciences has raised $150.0M across 1 funding round.
Korsana Biosciences has raised $150.0M in total across 1 funding round.
Korsana Biosciences has raised $150.0M across 1 funding round. Most recently, it raised $150.0M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 18, 2026 | $150M Series A | TCGX, Nilesh Kumar | Fairmount, Foresite Capital, Janus Henderson Investors, J.P. Morgan, Sanofi Ventures, Andrew Gottesdiener | Announced |
Korsana Biosciences has raised $150.0M in total across 1 funding round.
Korsana Biosciences's investors include TCGX, Nilesh Kumar, Fairmount, Foresite Capital, Janus Henderson Investors, J.P. Morgan, Sanofi Ventures, Andrew Gottesdiener.